264 related articles for article (PubMed ID: 22970981)
1. Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.
Horst SN; Kane S
Expert Opin Pharmacother; 2012 Oct; 13(15):2225-32. PubMed ID: 22970981
[TBL] [Abstract][Full Text] [Related]
2. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Kamm MA; Sandborn WJ; Gassull M; Schreiber S; Jackowski L; Butler T; Lyne A; Stephenson D; Palmen M; Joseph RE
Gastroenterology; 2007 Jan; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
[TBL] [Abstract][Full Text] [Related]
3. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
4. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
[TBL] [Abstract][Full Text] [Related]
5. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
6. Mesalamine with MMX technology for the treatment of ulcerative colitis.
Schreiber S; Kamm MA; Lichtenstein GR
Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
[TBL] [Abstract][Full Text] [Related]
7. Multi-matrix system mesalamine: to use or not to use.
Kale-Pradhan PB; Pradhan RS; Wilhelm SM
Ann Pharmacother; 2008 Feb; 42(2):265-9. PubMed ID: 18182473
[TBL] [Abstract][Full Text] [Related]
8. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
9. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
[TBL] [Abstract][Full Text] [Related]
10. Extended-release mesalamine granules for ulcerative colitis.
Love BL; Miller AD
Ann Pharmacother; 2012 Nov; 46(11):1529-36. PubMed ID: 23115226
[TBL] [Abstract][Full Text] [Related]
11. MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.
Hu MY; Peppercorn MA
Expert Opin Pharmacother; 2008 Apr; 9(6):1049-58. PubMed ID: 18377346
[TBL] [Abstract][Full Text] [Related]
12. MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.
Yang LP; McCormack PL
Drugs; 2011 Jan; 71(2):221-35. PubMed ID: 21275447
[TBL] [Abstract][Full Text] [Related]
13. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
[TBL] [Abstract][Full Text] [Related]
14. Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates.
Osterman MT; Lichtenstein GR
Methods Find Exp Clin Pharmacol; 2009; 31(1):41-6. PubMed ID: 19357797
[TBL] [Abstract][Full Text] [Related]
15. MMX mesalamine.
Baker DE
Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
[TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
Bonovas S; Nikolopoulos GK; Piovani D; González-Lorenzo M; Pantavou K; Lytras T; Peyrin-Biroulet L; Danese S
Br J Clin Pharmacol; 2019 Oct; 85(10):2244-2254. PubMed ID: 31269287
[TBL] [Abstract][Full Text] [Related]
17. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis.
Kane S; Katz S; Jamal MM; Safdi M; Dolin B; Solomon D; Palmen M; Barrett K
Inflamm Bowel Dis; 2012 Jun; 18(6):1026-33. PubMed ID: 21837775
[TBL] [Abstract][Full Text] [Related]
18. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
19. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
Sandborn WJ; Korzenik J; Lashner B; Leighton JA; Mahadevan U; Marion JF; Safdi M; Sninsky CA; Patel RM; Friedenberg KA; Dunnmon P; Ramsey D; Kane S
Gastroenterology; 2010 Apr; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
[TBL] [Abstract][Full Text] [Related]
20. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
Sandborn WJ; Travis S; Moro L; Jones R; Gautille T; Bagin R; Huang M; Yeung P; Ballard ED
Gastroenterology; 2012 Nov; 143(5):1218-1226.e2. PubMed ID: 22892337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]